When to pause and when to get care now

Tell the clinician what could change the visit

An infection, bleeding trouble, or a platelet problem needs a medical review. A platelet problem means those blood cells are too few or don’t work properly.

You may know from a blood test or a doctor’s warning about bleeding. Don’t change a prescription; take the full medicine list and recent health notes.

At QC Kinetix, joint preservation means a Chandler clinician may discuss PRP—made by separating your blood—as a non-surgical option, without promising joint repair. Blood thinners, aspirin, and some other medicines still matter.

Know the usual prp injection side effects

The usual prp injection side effects include brief soreness, swelling, and stiffness. Timing can differ with the sore area and your daily activity.

Before leaving, ask about the first evening and next morning. You’ll need a phone number, activity limits, and clear reasons to call.

How much soreness is normal? Mild soreness may happen early, but quickly rising pain or a new fever isn’t routine.

Get prompt help for warning signs

Fever with a swollen, hot joint can mean infection. New drainage, spreading warmth, or steadily rising pain also needs prompt care.

After an injury, get checked if you can’t bear weight or the joint looks bent. A sudden pop followed by lost arm or leg use may mean a torn tendon.

Go to an emergency department now for new weakness, numbness, lost bladder control, or foot drop, which means you suddenly can’t lift the front of your foot. Banner Ironwood Medical Center on Gantzel Road has a 24-hour emergency department.

Sources

1. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

2. A systematic review and meta-analysis of adverse events in randomized trials of intra-articular PRP for knee osteoarthritis found PRP associated with mild, transient adverse events - knee pain and swelling - that typically resolve without intervention, and more frequent with LEUKOCYTE-RICH formulations. Leukocyte-poor PRP had a safety profile similar to hyaluronic acid. Knee stiffness was more frequent with PRP than with normal saline (P=.031). No severe adverse events were reported in any group.

   Nakagawa HF, Kim J, Rabinowitz J, et al. — Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis. PM&R, 2026. DOI: 10.1002/pmrj.70141.

3. A Bayesian network meta-analysis of nine studies (six RCTs, 1055 patients) found leukocyte-POOR PRP produced significantly better WOMAC scores than hyaluronic acid (mean difference -21.14; 95% CI -39.63 to -2.65) and than placebo (-17.84; 95% CI -34.95 to -0.73), while leukocyte-RICH PRP showed no such significant difference versus placebo. PRP of either type caused more local adverse reactions than hyaluronic acid (OR 5.63; 95% CI 1.38-22.90), almost always local swelling and pain, with no difference in safety between the two PRP types.

   Riboh JC, Saltzman BM, Yanke AB, et al. — Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. American Journal of Sports Medicine, 2016. DOI: 10.1177/0363546515580787.

4. A prospective fixed-sequence controlled laboratory study in healthy men found that daily low-dose aspirin significantly reduced release of VEGF, PDGF-AB and TGF-beta1 from freshly isolated leukocyte-rich PRP when activated with arachidonic acid. This is the mechanistic basis for the routine instruction to review antiplatelet and NSAID use before a PRP draw - and the authors noted clinical studies are still needed to establish how much this matters in vivo.

   Jayaram P, Yeh P, Patel SJ, et al. — Effects of Aspirin on Growth Factor Release From Freshly Isolated Leukocyte-Rich Platelet-Rich Plasma in Healthy Men: A Prospective Fixed-Sequence Controlled Laboratory Study. American Journal of Sports Medicine, 2019. DOI: 10.1177/0363546519827294.

5. PATH-2 randomised 230 adults with acute Achilles tendon rupture managed non-surgically to PRP or a placebo dry-needle injection across 19 UK hospitals, with a central laboratory confirming the PRP was of good quality with the expected growth-factor content. At 24 weeks there was no detectable difference in muscle-tendon function (limb symmetry index 34.7% versus 38.5%; adjusted mean difference -3.9%; 95% CI -10.5% to 2.7%) or in any secondary outcome or adverse-event rate.

   Keene DJ, Alsousou J, Harrison P, et al. — Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ, 2019. DOI: 10.1136/bmj.l6132.